Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Despite current therapies, there remains an unmet need for treatment for patients with hemophilia. The main parts of two phase 2 trials established clinical proof-of-concept for once-daily, subcutaneous concizumab prophylaxis in patients with hemophilia A/B with inhibitors (HAwI/HBwI; explorer4) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Amy D., Angchaisuksiri, Pantep, Astermark, Jan, Benson, Gary, Castaman, Giancarlo, Eichler, Hermann, Jiménez-Yuste, Victor, Kavakli, Kaan, Matsushita, Tadashi, Poulsen, Lone Hvitfeldt, Wheeler, Allison P., Young, Guy, Zupančić-Šalek, Silva, Oldenburg, Johannes, Chowdary, Pratima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198939/
https://www.ncbi.nlm.nih.gov/pubmed/35290453
http://dx.doi.org/10.1182/bloodadvances.2021006403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198939/
https://www.ncbi.nlm.nih.gov/pubmed/35290453
http://dx.doi.org/10.1182/bloodadvances.2021006403

Ejemplares similares